Search results for: Vaccines
Filter search results
OHE Annual Lecture Webinar 2020: How Should the World Pay for a COVID-19 Vaccine?
24 June 2020, 11:00pm
…company’s up-front investment was for nothing? We have seen moves in a number of countries to restrict patent rights for COVID vaccines and therapies; but perceived intellectual property (IP) risk…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Five Questions We Think Matter a Lot
29 March 2019
…the US price (policies roughly equivalent to linking markets through price transparency) increases deadweight loss for drugs and vaccines by over 50%. They also find that a monopolist manufacturer of…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
…arrangements) that are key to efficient pricing and use of cancer medicines. This is a missed opportunity. WHO should also support differential pricing of on-patent drugs and vaccines, which is…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
23 September 2019
…in registration trials. There is an overlap between the elements of value that are relevant for vaccines and antibiotics. The advanced modelling approaches that are used for vaccines could be…
How Should the World Pay for a COVID-19 Vaccine?
26 May 2020, 12:00am
…COVID vaccines and therapies; but perceived Intellectual Property (IP) risk will inevitably deter private sector investment even when companies are willing to work for returns that recognise the nature of…
Does Government Funding Increase Public Sector Development of New Medicines?
5 March 2021
…vaccines despite there being a great need for them worldwide.5 To compensate for the potential gaps in private research funding, governments directly invest in pharmaceutical R&D particularly supporting drug development…
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
…Center for Biologics Evaluation and Research (CBER) for products such as vaccines and gene therapies. It is critical that CBO’s assumed baseline reflects reality. If new drug approvals are expected…
AIDS: Worldwide Policies and Problems
1 September 1991
…been learnt about its pathogenic mechanisms. Since the virus is integrated into genetic material and therefore replicates itself, it is very difficult to intervene in terms of vaccines or therapies….
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…2014. Accessed February 27, 2024. https://www.ohe.org/news/orphan-drugs-policies-suitable-case-treatment/ Kettler H, Towse A. Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty – OHE. OHE – Leading intellectual…